Search research articles
Contact Us
Filters
Showing results (271-280 of 328) with videos related to
Page
of 33
Sort By:
Nature Medicine
|
June 20, 2020
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
Priscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 3, 2024
Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records
Virginia H Sun, Julius C Heemelaar, Ibrahim Hadzic, et al.
Journal for Immunotherapy of Cancer
|
September 21, 2021
Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
Leyre Zubiri, Gabriel E Molina, Meghan J Mooradian, et al.
Lancet (London, England)
|
January 21, 2024
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
Jeffrey S Weber, Matteo S Carlino, Adnan Khattak, et al.
Nature Medicine
|
June 2, 2023
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results
Priscilla K Brastianos, Albert E Kim, Anita Giobbie-Hurder, et al.
Journal for Immunotherapy of Cancer
|
November 28, 2025
International real-world study of combination immunotherapy sequences in metastatic melanoma
Mora Guardamagna, Sarah E Lochrin, James William Smithy, et al.
Nature Communications
|
October 13, 2021
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
Priscilla K Brastianos, Matthew R Strickland, Eudocia Quant Lee, et al.
Nature Medicine
|
June 3, 2020
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
Priscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
Oncoimmunology
|
May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
Zachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 4, 2024
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
Rachel Woodford, Janet McKeown, Lotte L Hoeijmakers, et al.
Page
of 33
Search research articles
Search
Showing results (271-280 of 328) with videos related to
Sort By:
Page
of 33
Nature Medicine
|
June 20, 2020
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
Priscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 3, 2024
Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records
Virginia H Sun, Julius C Heemelaar, Ibrahim Hadzic, et al.
Journal for Immunotherapy of Cancer
|
September 21, 2021
Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
Leyre Zubiri, Gabriel E Molina, Meghan J Mooradian, et al.
Lancet (London, England)
|
January 21, 2024
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
Jeffrey S Weber, Matteo S Carlino, Adnan Khattak, et al.
Nature Medicine
|
June 2, 2023
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results
Priscilla K Brastianos, Albert E Kim, Anita Giobbie-Hurder, et al.
Journal for Immunotherapy of Cancer
|
November 28, 2025
International real-world study of combination immunotherapy sequences in metastatic melanoma
Mora Guardamagna, Sarah E Lochrin, James William Smithy, et al.
Nature Communications
|
October 13, 2021
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
Priscilla K Brastianos, Matthew R Strickland, Eudocia Quant Lee, et al.
Nature Medicine
|
June 3, 2020
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
Priscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
Oncoimmunology
|
May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
Zachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 4, 2024
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
Rachel Woodford, Janet McKeown, Lotte L Hoeijmakers, et al.
Page
of 33